CLINICAL TRIALS PROFILE FOR AZACITIDINE
✉ Email this page to a colleague
All Clinical Trials for azacitidine
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00004062 ↗ | Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer | Completed | National Cancer Institute (NCI) | Phase 1 | 1999-07-01 | RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer. |
NCT00004062 ↗ | Azacitidine to Restore Thyroid Function in Patients With Persistent or Metastatic Thyroid Cancer | Completed | Lucille P. Markey Cancer Center at University of Kentucky | Phase 1 | 1999-07-01 | RATIONALE: Azacitidine may help thyroid cancer cells regain the ability to take up iodine. This would allow the cancer to be detected and treated by radioactive iodine. PURPOSE: Phase I trial to study the effectiveness of azacitidine to restore thyroid function in treating patients who have persistent or metastatic thyroid cancer. |
NCT00004871 ↗ | Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | National Cancer Institute (NCI) | Phase 1 | 2000-05-01 | RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome. |
NCT00004871 ↗ | Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | Sidney Kimmel Comprehensive Cancer Center | Phase 1 | 2000-05-01 | RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome. |
NCT00004871 ↗ | Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 | 2000-05-01 | RATIONALE: Azacitidine plus phenylbutyrate may help leukemia cells develop into normal white blood cells. PURPOSE: Phase I trial to study the effectiveness of combining azacitidine and phenylbutyrate in treating patients who have acute myeloid leukemia or myelodysplastic syndrome. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for azacitidine
Condition Name
Clinical Trial Locations for azacitidine
Trials by Country
Clinical Trial Progress for azacitidine
Clinical Trial Phase
Clinical Trial Sponsors for azacitidine
Sponsor Name